RecruitingNCT06726720

UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

A Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating AstraZeneca (or Alliance Developed) Drugs


Sponsor

AstraZeneca

Enrollment

300 participants

Start Date

Dec 16, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in combination at any stage of disease. Three cohorts are designed, based on the stage of NSCLC (resectable, unresectable and metastatic). The multicohort study is modular in design. Specific modules will be set up separately to assess each new indication of drugs developed by AZ or as part of an AZ alliance once European marketing authorization (MA) has been granted and made available in the participating countries. Patients will be enrolled in the study if they have received (retrospective), receive (retrospective and prospective) or will receive (prospective) approved drugs developed by AZ or as part of an AZ alliance according to the eligibility criteria. Treatment plan and decision are made independently by each treating physician prior to inclusion in this study.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Adult patients (≥ 18 years old)
  • Patients with histologically or cytologically proven NSCLC
  • Patients initiated with approved drugs developed by AZ or as part of an AZ alliance at the time of the enrollment or within the previous three weeks.
  • Informed patients who consent to participate in the study as per local regulations.

Exclusion Criteria4

  • Patients participating in an interventional clinical trial for NSCLC\*
  • \* with the exception on low-interventional studies (RIPH2) where the intervention does not involve the NSCLC treatment
  • Patients already enrolled in another module of the cohort in UMBREALUNG
  • Patients under safeguard of justice, curatorship or guardianship

Locations(40)

Research Site

Troyes, France

Research Site

Valenciennes, France

Research Site

Vannes, France

Research Site

Aix-en-Provence, France

Research Site

Angers, France

Research Site

Aurillac, France

Research Site

Auxerre, France

Research Site

Avignon, France

Research Site

Blois, France

Research Site

Bordeaux, France

Research Site

Bourg-en-Bresse, France

Research Site

Carcassonne, France

Research Site

Chalon-sur-Saône, France

Research Site

Chambéry, France

Research Site

Châteauroux, France

Research Site

Créteil, France

Research Site

Dieppe, France

Research Site

Dinan, France

Research Site

Dreux, France

Research Site

Epagny Metz Tessy, France

Research Site

Le Coudray, France

Research Site

Limoges, France

Research Site

Lyon, France

Research Site

Marseille, France

Research Site

Meaux, France

Research Site

Metz, France

Research Site

Mulhouse, France

Research Site

Nancy, France

Research Site

Nantes, France

Research Site

Neuilly-sur-Seine, France

Research Site

Nice, France

Research Site

Nîmes, France

Research Site

Perpignan, France

Research Site

Saint-Brieuc, France

Research Site

Saint-Etienne, France

Research Site

Saint-Herblain, France

Research Site

Suresnes, France

Research Site

Toulouse, France

Research Site

Villefranche-sur-Saône, France

Research Site

Villeurbanne, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06726720